dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Inhibitors of apoptosis (IAP) protein family (type: other_protein)
Target: baculoviral IAP repeat containing 3

Ligand: xevinapant (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.289999961853027 pKi
Reference (Journal): A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.
Published in: J Med Chem
Target family: Inhibitors of apoptosis (IAP) protein family (type: other_protein)
Target: baculoviral IAP repeat containing 5

Ligand: compound III [PMID: 24080463] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.599999904632568 pIC50
Reference (Journal): Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
Published in: Bioorg Med Chem Lett
Target family: Inhibitors of apoptosis (IAP) protein family (type: other_protein)
Target: baculoviral IAP repeat containing 7

Ligand: GDC-0152 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 7.849999904632568 pKi
Reference (Journal): Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
Published in: J Med Chem
Target family: Inhibitors of apoptosis (IAP) protein family (type: other_protein)
Target: baculoviral IAP repeat containing 3

Ligand: AZD5582 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 7.679999828338623 pIC50
Reference (Journal): Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
Published in: J Med Chem

Ligand: GDC-0152 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 7.369999885559082 pKi
Reference (Journal): Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).
Published in: J Med Chem

Ligand: SM-122 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.739999771118164 pKi
Reference (Journal): Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases.
Published in: J Med Chem

Ligand: SM-337 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: yes
Median affinity: 8.380000114440918 pKi
Reference (Journal): Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases.
Published in: J Med Chem
Target family: Inhibitors of NF-kappaB (I&kappa;B) family proteins (type: other_protein)
Target: BCL3 transcription coactivator

Ligand: BCL3 inhibitor JS6 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.340000152587891 pIC50
Reference (Patent): 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: <i>N</i>-Acylphosphatidylethanolamine-phospholipase D

Ligand: ARN19874 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.46999979019165 pIC50
Reference (Journal): Synthesis and characterization of the first inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD).
Published in: Chem Commun (Camb.)
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: Fatty acid amide hydrolase

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.429999828338623 pKi
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.849999904632568 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega

Ligand: example 13 [WO2009109743] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.420000076293945 pIC50
Reference (Patent): Azetidine derivatives.

Ligand: (R)-ARN2508 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
Published in: Eur J Med Chem

Ligand: (S)-ARN2508 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.029999732971191 pIC50
Reference (Journal): Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies.
Published in: Eur J Med Chem

Ligand: JNJ1661010 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.800000190734863 pIC50
Reference (Journal): Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
Published in: Bioorg Med Chem Lett

Ligand: JNJ40355003 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.480000019073486 pIC50
Reference (Journal): Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.
Published in: ACS Med Chem Lett

Ligand: dual sEH/FAAH inhibitor 11 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.100000381469727 pIC50
Reference (Patent): Inhibitors for soluble epoxide hydrolase (seh) and fatty acid amide hydrolase (faah)
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: <i>N</i>-Acylethanolamine acid amidase

Ligand: S-OOPP (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.4 pIC50
Reference (Journal): Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Published in: Proc Natl Acad Sci USA

Ligand: F215 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
Published in: Pharmacol Res

Ligand: F215 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Identification of highly potent N-acylethanolamine acid amidase (NAAA) inhibitors: Optimization of the terminal phenyl moiety of oxazolidone derivatives.
Published in: Eur J Med Chem

Ligand: CCP (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase.
Published in: Biochem J

Ligand: ARN726 (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.199999809265137 pIC50
Reference (Journal): A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation.
Published in: ACS Chem Biol

Ligand: ARN726 (Synthetic organic)
Interaction type: Inhibitor
Action: Irreversible inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.570000171661377 pIC50
Reference (Journal): A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation.
Published in: ACS Chem Biol

Ligand: ARN19702 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.639999866485596 pIC50
Reference (Journal): Second-Generation Non-Covalent NAAA Inhibitors are Protective in a Model of Multiple Sclerosis.
Published in: Angew Chem Int Ed Engl
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: Fatty acid amide hydrolase-2

Ligand: URB597 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A second fatty acid amide hydrolase with variable distribution among placental mammals.
Published in: J Biol Chem

Ligand: URB597 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Published in: Anesth Analg

Ligand: OL135 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Published in: Anesth Analg

Ligand: OL135 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A second fatty acid amide hydrolase with variable distribution among placental mammals.
Published in: J Biol Chem

Ligand: LY2077855 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Published in: Anesth Analg

Ligand: JNJ1661010 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.239999771118164 pIC50
Reference (Journal): Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Published in: Anesth Analg

Ligand: ASP8477 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.239999771118164 pIC50
Reference (Journal): In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor.
Published in: Eur J Pharmacol
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: Fatty acid amide hydrolase

Ligand: URB937 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
Published in: J Med Chem

Ligand: URB597 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): A second fatty acid amide hydrolase with variable distribution among placental mammals.
Published in: J Biol Chem

Ligand: UCM1341 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.069999694824219 pIC50
Reference (Journal): Identification of Bivalent Ligands with Melatonin Receptor Agonist and Fatty Acid Amide Hydrolase (FAAH) Inhibitory Activity That Exhibit Ocular Hypotensive Effect in the Rabbit.
Published in: J Med Chem

Ligand: SA-57 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.489999771118164 pIC50
Reference (Journal): O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.
Published in: ACS Chem Neurosci

Ligand: SA-57 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.720000267028809 pIC50
Reference (Journal): O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.
Published in: ACS Chem Neurosci

Ligand: PF750 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity.
Published in: Biochemistry

Ligand: PF750 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.1899995803833 pIC50
Reference (Journal): Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors.
Published in: ACS Omega
Target family: <i>N</i>-Acylethanolamine turnover (type: enzyme)
Target: <i>N</i>-Acylphosphatidylethanolamine-phospholipase D

Ligand: LEI-401 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.570000171661377 pKi
Reference (Journal): Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice.
Published in: Nat Chem Biol

Ligand: hexachlorophene (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1949)
Primary target: no
Median affinity: 5.010000228881836 pIC50
Reference (Journal): Symmetrically substituted dichlorophenes inhibit <i>N</i>-acyl-phosphatidylethanolamine phospholipase D.
Published in: J Biol Chem

Ligand: bithionol (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 4.96999979019165 pIC50
Reference (Journal): Symmetrically substituted dichlorophenes inhibit <i>N</i>-acyl-phosphatidylethanolamine phospholipase D.
Published in: J Biol Chem
Target family: Inositol 1,4,5-trisphosphate 3-kinases (type: enzyme)
Target: IP<sub>3</sub> kinase A

Ligand: GNF362 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Journal): Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease.
Published in: PLoS ONE
Target family: Inositol 1,4,5-trisphosphate 3-kinases (type: enzyme)
Target: IP<sub>3</sub> kinase C

Ligand: GNF362 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease.
Published in: PLoS ONE
Target family: Inositol 1,4,5-trisphosphate 3-kinases (type: enzyme)
Target: IP<sub>3</sub> kinase B

Ligand: GNF362 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Inhibition of the Inositol Kinase Itpkb Augments Calcium Signaling in Lymphocytes and Reveals a Novel Strategy to Treat Autoimmune Disease.
Published in: PLoS ONE
Target family: Inositol monophosphatase (type: enzyme)
Target: IMPase 1

Ligand: Li+ (Inorganic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1970)
Primary target: yes
Median affinity: 3.5 pKi
Reference (Journal): cDNA cloning of human and rat brain myo-inositol monophosphatase. Expression and characterization of the human recombinant enzyme.
Published in: Biochem J
Target family: Inositol polyphosphate phosphatases (type: enzyme)
Target: INPP5D

Ligand: 3 alpha-aminocholestane (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells.
Published in: J Immunol

Ligand: rosiptor (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo.
Published in: Br J Pharmacol
Target family: Inositol polyphosphate phosphatases (type: enzyme)
Target: INPP5A

Ligand: compound 5 [Noble et al., 1992] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.889999866485596 pKi
Reference (Journal): Total synthesis of myo-inositol-1-phosphate-4,5-pyrophosphate, a novel second messenger analogue, via myo-inositol-1-phosphate-4,5-bisphosphorothioate
Published in: Bioorg Med Chem Lett
Target family: Inositol polyphosphate phosphatases (type: enzyme)
Target: SYNJ2

Ligand: example 15 [WO2015079413] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.059999942779541 pIC50
Reference (Patent): Synaptojanin-2 inhibitors and uses thereof
Target family: Inositol polyphosphate phosphatases (type: enzyme)
Target: INPPL1

Ligand: AS1949490 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.210000038146973 pIC50
Reference (Journal): Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.
Published in: Br J Pharmacol
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor)

Ligand: carotegrast methyl (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity:  -
Reference (Journal): AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.
Published in: Br J Clin Pharmacol
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;V&beta;3

Ligand: CWHM12 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.100000381469727 pIC50
Reference (Journal): Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs.
Published in: Nat Med

Ligand: cilengitide (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.5 pIC50
Reference (Journal): Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins.
Published in: J Med Chem
Target family: Integrins (type: catalytic_receptor)
Target: integrin, alpha L subunit (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)

Ligand: rovelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Inhibition of in vivo neutrophil transmigration by a novel humanized anti-CD11/CD18 monoclonal antibody.
Published in: Cytokines Cell Mol Ther

Ligand: rovelizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia.
Published in: Exp Neurol

Ligand: lifitegrast (Synthetic organic)
Interaction type: Antagonist
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2016)
Primary target: yes
Median affinity:  -
Reference (Journal): Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye.
Published in: ACS Med Chem Lett

Ligand: lifitegrast (Synthetic organic)
Interaction type: Antagonist
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2016)
Primary target: yes
Median affinity:  -
Reference (Patent): Small molecule lfa-1 inhibitors

Ligand: efalizumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: yes
Approval source: FDA (2003), EMA (2004)
Primary target: yes
Median affinity: 11.399999618530273 pKd
Reference (Patent): Method of treatment using humanized anti-CD11a antibodies.

Ligand: BIRT 377 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pKd
Reference (Journal): Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion.
Published in: J Immunol

Ligand: BI-1950 (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pKd
Reference (Webpage): LFA-1 (lymphocyte function-associated antigen-1) antagonist | BI-1950
Target family: Integrins (type: catalytic_receptor)
Target: integrin &alpha;L&beta;2

Ligand: A286982 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.
Published in: J Med Chem